|
|||
![]() |
A proactive approach to treatment
Paolo Lanzetta will introduce the importance of proactive treatment for achieving and maintaining positive outcomes in nAMD, and highlight the key data supporting the use of aflibercept with a treat-and-extend regimen.
Treat-and-extend with aflibercept:
Gemmy Cheung will present the latest results from the ALTAIR study, adding to the evidence supporting the use of a proactive treat-and-extend regimen with aflibercept in nAMD.
Treat-and-extend with aflibercept:
Paul Mitchell will present emerging evidence from the ARIES study on the use of aflibercept with early versus late initiation of treatment interval extension.
Q&A with the experts
| As a leader in medical retina, Bayer is hosting a series of ophthalmology webinars to reflect its mission to support science for better lives, and enhance patient care and experience, by sharing best practices within the ophthalmology community. You are invited to join global experts Professor Paolo Lanzetta, Associate Professor Gemmy Cheung, and Professor Paul Mitchell in a webinar on the topic of proactive, extended dosing with aflibercept. The European SPC for aflibercept solution for intravitreal injection can be found here.
THANK YOU FOR YOUR INTEREST
This is a promotional webinar organized and funded by Bayer. Bayer recommends the use of its products in line with local prescribing information.
By registering, you hereby authorize Bayer AG (hereinafter "us", "our", or "we") as well as other Bayer affiliates involved in managing a service or communication towards you, to directly deliver marketing/medical communications to you through emails or other electronic communications containing information about services, products, or events related to your medical interest ("Electronic Marketing/Medical Communications"), as well as to analyze your use of our Electronic Marketing/Medical Communications in order to enable customization of Electronic Marketing/Medical Communications to meet your needs and preferences.
You are free to revoke your consent at any time with future effect. Please address your declaration of revocation to privacy_ch@bayer.com. Furthermore, every Electronic Marketing/Medical Communication we send to you includes an option for you to revoke your consent by clicking an unsubscribe link.
By submitting this form, you agree to provide your contact information to Bayer and their privacy policy.
PP-EYL-ALL-0215-1
|